on BIOSYNEX (EPA:ALBIO)
BIOSYNEX: Revenue for the first half of 2024 up 26%
In the first half of 2024, Biosynex recorded a turnover of 53.8 million euros, an increase of 26% compared to the same period in 2023. On a like-for-like basis, this growth is 6%.
Strategic acquisitions made in 2022 and 2023 made a significant contribution to this performance. In addition, the American subsidiaries now represent 22% of total turnover and are showing significant growth.
The share of turnover from exports is 49%, up 11 points compared to 2023. Biosynex also plans to strengthen its American revenues, in particular with the PROCISEDX and CHEMBIO tests.
In the coming months, the company plans to continue strengthening its commercial activity in Europe, the United States and emerging countries, while focusing on high value-added R&D projects.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news